These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 8558530)

  • 1. Substituted (pyrroloamino)pyridines: potential agents for the treatment of Alzheimer's disease.
    Davis L; Olsen GE; Klein JT; Kapples KJ; Huger FP; Smith CP; Petko WW; Cornfeldt M; Effland RC
    J Med Chem; 1996 Jan; 39(2):582-7. PubMed ID: 8558530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeutic agents for Alzheimer's disease.
    Klein JT; Davis L; Olsen GE; Wong GS; Huger FP; Smith CP; Petko WW; Cornfeldt M; Wilker JC; Blitzer RD; Landau E; Haroutunian V; Martin LL; Effland RC
    J Med Chem; 1996 Jan; 39(2):570-81. PubMed ID: 8558529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A geometry optimization and molecular electrostatic potential mapping study of structure-activity relationship for some anti-Alzheimer agents.
    Kushwaha PS; Shukla MK; Mishra PC
    Indian J Biochem Biophys; 1999 Apr; 36(2):101-6. PubMed ID: 10549169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Muscarinic receptor 1 agonist activity of novel N-arylthioureas substituted 3-morpholino arecoline derivatives in Alzheimer's presenile dementia models.
    Malviya M; Kumar YC; Asha D; Chandra JN; Subhash MN; Rangappa KS
    Bioorg Med Chem; 2008 Aug; 16(15):7095-101. PubMed ID: 18640043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of novel N-aryl sulfonamide substituted 3-morpholino arecoline derivatives as muscarinic receptor 1 agonists in Alzheimer's dementia models.
    Kumar YC; Malviya M; Chandra JN; Sadashiva CT; Kumar CS; Prasad SB; Prasanna DS; Subhash MN; Rangappa KS
    Bioorg Med Chem; 2008 May; 16(9):5157-63. PubMed ID: 18359231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FK506-binding protein ligands: structure-based design, synthesis, and neurotrophic/neuroprotective properties of substituted 5,5-dimethyl-2-(4-thiazolidine)carboxylates.
    Zhao L; Huang W; Liu H; Wang L; Zhong W; Xiao J; Hu Y; Li S
    J Med Chem; 2006 Jul; 49(14):4059-71. PubMed ID: 16821768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis, characterization and anticonvulsant activity evaluation of some 1,4-dihydropyridines and 3,5-(substituted)oxycarbonyl-1,4-dihydro-2,6-dimethyl-N-[2-(4-sulfamoylphenylamino)-acetyl]-4-(substituted)pyridines.
    Subudhi BB; Panda PK; Swain SP; Sarangi P
    Acta Pol Pharm; 2009; 66(2):147-53. PubMed ID: 19719048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis of 2,6-diaryl-substituted pyridines and their antitumor activities.
    Son JK; Zhao LX; Basnet A; Thapa P; Karki R; Na Y; Jahng Y; Jeong TC; Jeong BS; Lee CS; Lee ES
    Eur J Med Chem; 2008 Apr; 43(4):675-82. PubMed ID: 17673337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and structure-activity relationship of novel thiophene derivatives for beta-amyloid plaque imaging.
    Chandra R; Kung MP; Kung HF
    Bioorg Med Chem Lett; 2006 Mar; 16(5):1350-2. PubMed ID: 16325402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and evaluation of two 18F-labeled imidazo[1,2-a]pyridine analogues as potential agents for imaging beta-amyloid in Alzheimer's disease.
    Zeng F; Southerland JA; Voll RJ; Votaw JR; Williams L; Ciliax BJ; Levey AI; Goodman MM
    Bioorg Med Chem Lett; 2006 Jun; 16(11):3015-8. PubMed ID: 16574411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aryl 1-but-3-ynyl-4-phenyl-1,2,3,6-tetrahydropyridines as potential antipsychotic agents: synthesis and structure-activity relationships.
    Glase SA; Akunne HC; Heffner TG; Jaen JC; MacKenzie RG; Meltzer LT; Pugsley TA; Smith SJ; Wise LD
    J Med Chem; 1996 Aug; 39(16):3179-87. PubMed ID: 8759640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modification of the structure of 4, 6-disubstituted 2-(4-alkyl-1-piperazinyl)pyridines: synthesis and their 5-HT2A receptor activity.
    Paluchowska MH; Bojarski AJ; Bugno R; Charakchieva-Minol S; Wesołowska A
    Arch Pharm (Weinheim); 2003 Apr; 336(2):104-10. PubMed ID: 12761763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, corticotropin-releasing factor receptor binding affinity, and pharmacokinetic properties of triazolo-, imidazo-, and pyrrolopyrimidines and -pyridines.
    Chorvat RJ; Bakthavatchalam R; Beck JP; Gilligan PJ; Wilde RG; Cocuzza AJ; Hobbs FW; Cheeseman RS; Curry M; Rescinito JP; Krenitsky P; Chidester D; Yarem JA; Klaczkiewicz JD; Hodge CN; Aldrich PE; Wasserman ZR; Fernandez CH; Zaczek R; Fitzgerald LW; Huang SM; Shen HL; Wong YN; Chien BM; Arvanitis A
    J Med Chem; 1999 Mar; 42(5):833-48. PubMed ID: 10072681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new therapeutic approach in Alzheimer disease: some novel pyrazole derivatives as dual MAO-B inhibitors and antiinflammatory analgesics.
    Gökhan-Kelekçi N; Yabanoğlu S; Küpeli E; Salgin U; Ozgen O; Uçar G; Yeşilada E; Kendi E; Yeşilada A; Bilgin AA
    Bioorg Med Chem; 2007 Sep; 15(17):5775-86. PubMed ID: 17611112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and biological characterization of 1,4,5,6-tetrahydropyrimidine and 2-amino-3,4,5,6-tetrahydropyridine derivatives as selective m1 agonists.
    Messer WS; Abuh YF; Liu Y; Periyasamy S; Ngur DO; Edgar MA; El-Assadi AA; Sbeih S; Dunbar PG; Roknich S; Rho T; Fang Z; Ojo B; Zhang H; Huzl JJ; Nagy PI
    J Med Chem; 1997 Apr; 40(8):1230-46. PubMed ID: 9111297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological evaluation of novel Alzheimer's disease therapeutics: acetylcholinesterase inhibitors related to galanthamine.
    Bores GM; Huger FP; Petko W; Mutlib AE; Camacho F; Rush DK; Selk DE; Wolf V; Kosley RW; Davis L; Vargas HM
    J Pharmacol Exp Ther; 1996 May; 277(2):728-38. PubMed ID: 8627552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ispronicline (Targacept).
    Geerts H
    Curr Opin Investig Drugs; 2006 Jan; 7(1):60-9. PubMed ID: 16425673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Muscarinic receptor 1 agonist activity of novel N-aryl carboxamide substituted 3-morpholino arecoline derivatives in Alzheimer's presenile dementia models.
    Malviya M; Kumar YC; Mythri RB; Venkateshappa C; Subhash MN; Rangappa KS
    Bioorg Med Chem; 2009 Aug; 17(15):5526-34. PubMed ID: 19595599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-activity relationship of imidazo[1,2-a]pyridines as ligands for detecting beta-amyloid plaques in the brain.
    Zhuang ZP; Kung MP; Wilson A; Lee CW; Plössl K; Hou C; Holtzman DM; Kung HF
    J Med Chem; 2003 Jan; 46(2):237-43. PubMed ID: 12519062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1,1'-Xylyl bis-1,4,8,11-tetraaza cyclotetradecane: a new potential copper chelator agent for neuroprotection in Alzheimer's disease. Its comparative effects with clioquinol on rat brain copper distribution.
    Moret V; Laras Y; Pietrancosta N; Garino C; Quéléver G; Rolland A; Mallet B; Norreel JC; Kraus JL
    Bioorg Med Chem Lett; 2006 Jun; 16(12):3298-301. PubMed ID: 16581247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.